AbbVie Reports Topline Results from Phase 3 TEMPO-2 Trial of Tavapadon in Parkinson’s
Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
AbbVie Announces Positive Topline Results from Phase 3 for Tavapadon in Parkinson's
Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2024
Cerevel Reports Positive Results for Tavapadon in Phase 3 Trial for Parkinson's
Details : CVL-751 (tavapadon) is the first and only D1/D5 receptor partial agonist, which is being studied as a once-daily treatment for patients with parkinson’s disease.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2024
AbbVie Completes Acquisition of Cerevel Therapeutics
Details : Through the acquisition, Abbvie will leverage the Cerevel pipeline, which includes CVL-75 (tavapadon), a late-stage product, D1/D5 selective partial agonist for the treatment of Parkinson's disease.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : $8,700.0 million
January 08, 2024
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
Details : Cerevel will present data demonstrating consistent clinical pharmacology across a wide range of doses of tavapadon in several Phase 1 clinical trials, supporting its potential as a promising next-generation treatment for Parkinson’s disease.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2022
Details : The Non-Dilutive Financing will fund the full Phase 3 development program for tavapadon in Parkinson’s disease, also known as the TEMPO trials.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 13, 2021
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
Details : Cerevel Therapeutics' lead drug Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolera...
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2021
Details : Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. The Phase 3 program will evaluate the efficacy, safety and tolerability of fixed doses (TEMPO-1) and flexible doses (TEMPO-2) of ta...
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2020
Details : Studies to enroll approximately 1,200 patients to determine effectiveness of tavapadon across the full spectrum of early- and late-stage parkinson’s.
Product Name : CVL-751
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2020
Reset All
